



Programme

MONDAY, 25th October - 12 to 15.30 CET

Session 1 – COVID -19 pandemic, where we are?

12.00-12.20	Opening talk on ICGEB response to COVID	Lawrence Banks , ICGEB, Trieste, Italy
12.20-12.40	The challenges in Covid 19 testing in response to the pandemic in resources constrain countries: Nigeria experience	Marycelin Baba , University of Maiduguri, Nigeria
12.40-13.00	Research in times of the COVID-19 pandemic: A view of the WHO R&D Blueprint	Cesar Muñoz-Fontela , Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
13.00-13.20	Public Health Diagnosis: the Slovenian experience	Miroslav Petrovec , Institute of Microbiology and Immunology, Ljubljana, Slovenia
13.20-13.30	<i>Break</i>	

Session 2 – Mechanisms of disease

13.30-13.50	<i>Title to be advised</i>	IFOM, Milano, Italy
13.50-14.05	Development and production of an RT-qPCR diagnostic kit for the SARS-CoV-2 coronavirus.	Abla Djebbar University Hassiba Benbouali of Chlef, Algeria - <i>CRP awardee</i>
14.05-14.20	Facing the coronavirus crisis: Genomic evolution of SARS-CoV-2	Marta Giovanetti , Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil - <i>CRP awardee</i>
14.20-14.35	Design and application of nanoparticle formulations into a new platform technology for therapeutic antibody production against SARS-CoV-2	Hilda Minerva González Sánchez , Instituto Nacional de Salud Pública, Morelos, Mexico - <i>CRP awardee</i>
14.35-14.55	SARS-CoV-2 Reverse Genetics	Pei-Yong Shi , University of Texas Medical Branch, Galveston, USA
14.55-15.30	<i>Meet the speakers</i>	

TUESDAY, 26th October - 12 to 15.30 CET

Session 3 – Drugs

12.00-12.20	COVID-19: from lung pathology to novel drug discovery	Mauro Giacca , King's College London, UK and ICGEB Trieste, Italy
12.20-12.40	Antiviral drug discovery	Alessandro Marcello ICGEB Trieste, Italy
12.40-12.55	Focused drug discovery against SARS-CoV-2: Targeting cell invasion and replication	Gloria Virginia López , Institut Pasteur de Montevideo, Uruguay - <i>CRP awardee</i>
12.55-13.10	<i>Break</i>	

Session 4– Vaccines and immunity

13.10-13.30	How did COVID-19 vaccine development benefit from mRNA cancer vaccine platform?	Fulvia Vascotto , TRON, Mainz, Germany
13.30-13.50	Human Monoclonal Antibodies to SARS-CoV-2	Anmol Chandele , ICGEB New Delhi, India
13.50-14.05	Distribution of COVID-19 associated genetic variants across biobanks from Latin America and the Pacific	Andrés Moreno-Estrada , Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional - CINVESTAV, Guanajuato, Mexico - <i>CRP awardee</i>
14.05-14.20	Detection of SARS CoV-2 virus antibodies in both domestic and wild animals in Kenya	Tindih Shelton Heshborne , School of Pure and Applied Sciences, Machakos University, Kenya - <i>CRP awardee</i>
14.20-14.40	Cigarette smoke and Covid-19: a complex interaction	Francesca Polverino , University of Arizona College of Medicine, Tucson, USA
14.40-15.00	<i>Closing remarks</i>	Serena Zacchigna , ICGEB Trieste, Italy
15.00-15.30	<i>Meet the speakers</i>	